Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies.

In this preclinial trial, the AML cell line KG1 with FGFR1OP2-FGFR1 mutation was treated with Ponatinib. This drug effectively inhibits both FGFR phosphorylation and viability for KG1 cells at IC50 va… (full text at CIViC)

PMID 21482694 · Gozgit et al., 2011 · Open in CIViC

In this preclinial trial, the AML cell line EOL1 with FIP1L1-PDGFR alpha mutation was treated with Ponatinib. This drug effectively inhibits both PDGFR phosphorylation and viability for EOL1 cells at … (full text at CIViC)

PMID 21482694 · Gozgit et al., 2011 · Open in CIViC

In a preclinical trial, EOL1 AML cell lines with the FIP1L1-PDGFRa fusion mutation were treated with the tyrosine kinase inhibitors (TKI) ponatinib, sorafenib, and sunitinib. Ponatinib was similarly e… (full text at CIViC)

PMID 21482694 · Gozgit et al., 2011 · Open in CIViC

In a preclinical trial, the AML cell line EOL1with the FIP1L1-PDGFRa fusion mutation was treated with the tyrosine kinase inhibitors (TKI) ponatinib, sorafenib, and sunitinib. Ponatinib was similarly … (full text at CIViC)

PMID 21482694 · Gozgit et al., 2011 · Open in CIViC

In a preclinical trial, multiple experiments testing the effectiveness of ponatinib on the mutation FLT3-ITD in acute myeloid leukemia (AML) were conducted. Ponatinib was very effective in targeting t… (full text at CIViC)

PMID 21482694 · Gozgit et al., 2011 · Open in CIViC

In a preclinical trial, MV4-11 leukemic cell lines with the FLT3-ITD mutation and RS4;11 leukemic cell lines with the native FLT3 gene were treated with the tyrosine kinase inhibitors (TKI) ponatinib,… (full text at CIViC)

PMID 21482694 · Gozgit et al., 2011 · Open in CIViC

In a preclinical trial, MV4-11 leukemic cell lines with the FLT3-ITD mutation and RS4;11 leukemic cell lines with the native FLT3 gene were treated with the tyrosine kinase inhibitors (TKI) ponatinib,… (full text at CIViC)

PMID 21482694 · Gozgit et al., 2011 · Open in CIViC

In a preclinical trial, the leukemic cell line MV4-11 with the FLT3-ITD mutation and the leukemic cell line RS4;11 with the native FLT3 gene were treated with the tyrosine kinase inhibitors (TKI) pona… (full text at CIViC)

PMID 21482694 · Gozgit et al., 2011 · Open in CIViC

In a preclinical trial, MV4-11 leukemic cell lines with the FLT3-ITD mutation and RS4;11 leukemic cell lines with the native FLT3 gene were treated with the tyrosine kinase inhibitors (TKI) ponatinib,… (full text at CIViC)

PMID 21482694 · Gozgit et al., 2011 · Open in CIViC

In this preclinial trial, the AML cell line Kasumi-1 with c-KIT N822K mutation was treated with Ponatinib. This drug effectively inhibits both KIT phosphorylation and viability for Kasumi-1 cells at I… (full text at CIViC)

PMID 21482694 · Gozgit et al., 2011 · Open in CIViC

In a preclinical trial, the AML cell line Kasumi-1 with the KIT mutation N822K was treated with the tyrosine kinase inhibitors (TKI) ponatinib, sorafenib, and sunitinib. Ponatinib was much more effect… (full text at CIViC)

PMID 21482694 · Gozgit et al., 2011 · Open in CIViC

In a preclinical trial, Kasumi-1 AML cell lines with the KIT mutation N822K were treated with the tyrosine kinase inhibitors (TKI) ponatinib, sorafenib, and sunitinib. Ponatinib was much more effectiv… (full text at CIViC)

PMID 21482694 · Gozgit et al., 2011 · Open in CIViC

In a preclinical trial, the AML cell line KG1 with the FGFR1OP2-FGFR1 fusion mutation was treated with the tyrosine kinase inhibitors (TKI) ponatinib, sorafenib, and sunitinib. Ponatinib was much more… (full text at CIViC)

PMID 21482694 · Gozgit et al., 2011 · Open in CIViC

In a preclinical trial, KG1 AML cell lines with the FGFR1OP2-FGFR1 fusion mutation were treated with the tyrosine kinase inhibitors (TKI) ponatinib, sorafenib, and sunitinib. Ponatinib was much more e… (full text at CIViC)

PMID 21482694 · Gozgit et al., 2011 · Open in CIViC